Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guides On Bioequivalence Studies And COVID-19

Offers Advice On Protecting Participants In Studies For ANDAs

Executive Summary

Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.

You may also be interested in...



ANDA Guidance Says Yes To Limited Stability Data, No To Expired Reference Product During COVID

US FDA's updated Q&A guidance on developing generics for submission via the abbreviated new drug application pathway during the COVID-19 pandemic has been published.

FDA Updates Guidance On ANDAs During COVID

Updated Q&A guidance on developing generics for submission via the abbreviated new drug application pathway during the COVID-19 pandemic has been published by the FDA.

ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel